VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 14, 2026
Stock Comparison
AbbVie Inc. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AbbVie Inc.
ABBV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.
View ABBV analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 65 / 100 for AbbVie Inc.).
- Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Amgen Inc. has 5 across 3.
Primary market context
AbbVie Inc.
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Global
Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients
Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)
47.4%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
AbbVie Inc. strengths
No unique moat types yet.
Amgen Inc. strengths
Segment mix
AbbVie Inc. segments
Full profile >Immunology
Oligopoly
Oncology
Competitive
Neuroscience
Competitive
Aesthetics
Oligopoly
Eye Care
Competitive
Other Key Products
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.